Similar Efficacy Seen for Isodose, Dose-Escalated MHFRT, CFRT in Prostate Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, April 1, 2025 -- For patients with prostate cancer, isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally fractionated radiotherapy (CFRT), but bowel toxicity is seen in association with dose-escalated MHFRT, according to a study published online March 17 in The Lancet Oncology.
Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted an individual patient data meta-analysis from randomized phase 3 trials of CFRT versus MHFRT for prostate cancer. Seven phase 3 trials were eligible for inclusion; data were obtained for 3,454 patients from three trials comparing CFRT to isodose MHFRT and 2,426 patients from four trials comparing CFRT to dose-escalated MHFRT.
The researchers found no differences in progression-free survival at a median follow-up of 5.4 years for isodose MHFRT and 7.1 years for dose-escalated MHFRT. For isodose and dose-escalated MHFRT, there were no increased odds of grade 2 or higher genitourinary toxic effects. With dose-escalated, but not isodose MHFRT, the odds of grade 2 or higher gastrointestinal toxic effects were significantly greater (odds ratio, 1.48). Odds of urinary quality-of-life decrement or bowel quality-of-life decrement were no different for isodose MHFRT. Greater odds of bowel quality-of-life decrement were seen with dose-escalated MHFRT (odds ratio, 1.68), but no greater urinary quality-of-life decrement was seen.
"This meta-analysis provides the strongest evidence to date suggesting an isodose MHFRT regimen could be the preferred MHFRT regimen for all risk groups," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Advanced Biological Age Linked to Increased Risk for Incident Dementia
FRIDAY, May 2, 2025 -- Advanced biological age (BA) may be a risk factor for incident dementia, according to a study published online April 30 in Neurology. Yacong Bo, Ph.D...
Exposure to Smoke Pollution Ups Risk for Hospitalization for Respiratory Disease
FRIDAY, May 2, 2025 -- For older adults in the Western United States, exposure to high levels of smoke pollution is associated with an increase in hospitalizations for respiratory...
Exercise Helps Reduce Side Effects From Cancer Treatment
THURSDAY, May 1, 2025 -- Exercise mitigates adverse outcomes associated with cancer and its treatments, according to a review published online April 29 in the British Journal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.